Clinical efficacy of gamma-oryzanol combined with Femoston for perimenopausal syndrome

Table 1 Comparative analysis of baseline data

Factors	Control group (n = 59)	Observation group (n = 60)	χ2/t	P value
Age (years)	46.29 ± 6.47	45.97 ± 5.33	0.295	0.769
Disease course (months)	5.98 ± 0.94	6.17 ± 1.45	0.847	0.399
Body mass (kg)	60.83 ± 7.05	60.05 ± 7.71	0.576	0.566
Kupperman index (points)	28.51 ± 10.37	30.25 ± 11.89	0.850	0.397
Family medical history			1.245	0.265
With, n (%)	9 (15.25)	14 (23.33)
Without, n (%)	50 (84.75)	46 (76.67)

Table 2 Comparative analysis of clinical effectiveness, n (%)

Efficacy assessment	Control group (n = 59)	Observation group (n = 60)	χ2	P value
Markedly effective	18 (30.51)	35 (58.33)
Effective	24 (40.68)	21 (35.00)
Ineffective	17 (28.81)	4 (6.67)
Total effective rate	42 (71.19)	56 (93.33)	10.040	0.002

Table 3 Comparative analysis of safety, n (%)

Adverse reactions	Control group (n = 59)	Observation group (n = 60)	χ2	P value
Dizziness and headache	2 (3.39)	0 (0.00)
Nausea and vomiting	3 (5.08)	0 (0.00)
Breast tenderness	4 (6.78)	2 (3.33)
Total	9 (15.25)	2 (3.33)	5.039	0.025